Literature DB >> 24395722

Beyond antibodies: new affinity reagents to unlock the proteome.

Bridget Lollo1, Fintan Steele, Larry Gold.   

Abstract

Antibodies have been the workhorse reagents of protein capture and quantification since their 1959 debut in the RIAs developed by Yalow and Berson. However, there are technical challenges to the use of antibodies in highly multiplexed arrays aimed at measuring hundreds or even thousands of proteins at one time. We describe here a recently developed class of synthetic protein-binding reagents (slow off-rate modified aptamer). We discuss the chemical makeup and protein binding specifications of slow off-rate modified aptamer reagents, compare them to traditional aptamers and antibodies, briefly describe the novel proteomic assay that takes advantage of their unique properties, and provide several examples of their multiple applications to biomarker discovery and validation across a range of biomedical science questions.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Keywords:  Aptamer; Biomarker; Protein arrays; SOMAmer; SOMAscan

Mesh:

Substances:

Year:  2014        PMID: 24395722     DOI: 10.1002/pmic.201300187

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  38 in total

1.  Identification of Plasma Proteome Signatures Associated With Surgery Using SOMAscan.

Authors:  Tamara G Fong; Noel Y Chan; Simon T Dillon; Wenxiao Zhou; Bridget Tripp; Long H Ngo; Hasan H Otu; Sharon K Inouye; Sarinnapha M Vasunilashorn; Zara Cooper; Zhongcong Xie; Edward R Marcantonio; Towia A Libermann
Journal:  Ann Surg       Date:  2021-04-01       Impact factor: 12.969

Review 2.  Tapping the RNA world for therapeutics.

Authors:  Judy Lieberman
Journal:  Nat Struct Mol Biol       Date:  2018-04-16       Impact factor: 15.369

Review 3.  Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Authors:  Alice S Chen-Plotkin
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

4.  A polymer nanoparticle with engineered affinity for a vascular endothelial growth factor (VEGF165).

Authors:  Hiroyuki Koide; Keiichi Yoshimatsu; Yu Hoshino; Shih-Hui Lee; Ai Okajima; Saki Ariizumi; Yudai Narita; Yusuke Yonamine; Adam C Weisman; Yuri Nishimura; Naoto Oku; Yoshiko Miura; Kenneth J Shea
Journal:  Nat Chem       Date:  2017-03-27       Impact factor: 24.427

5.  Multi-Omics Profiling of the Tumor Microenvironment.

Authors:  Oliver Van Oekelen; Alessandro Laganà
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

6.  Serum Protein Signatures Using Aptamer-Based Proteomics for Minimal Change Disease and Membranous Nephropathy.

Authors:  Daniel A Muruve; Hanna Debiec; Simon T Dillon; Xuesong Gu; Emmanuelle Plaisier; Handan Can; Hasan H Otu; Towia A Libermann; Pierre Ronco
Journal:  Kidney Int Rep       Date:  2022-04-14

Review 7.  Proteomics in Chronic Arthritis-Will We Finally Have Useful Biomarkers?

Authors:  Christoph Kessel; Angela McArdle; Emely Verweyen; Toni Weinhage; Helmut Wittkowski; Stephen R Pennington; Dirk Foell
Journal:  Curr Rheumatol Rep       Date:  2018-07-14       Impact factor: 4.592

Review 8.  Novel Strategies to Address the Challenges in Top-Down Proteomics.

Authors:  Jake A Melby; David S Roberts; Eli J Larson; Kyle A Brown; Elizabeth F Bayne; Song Jin; Ying Ge
Journal:  J Am Soc Mass Spectrom       Date:  2021-05-13       Impact factor: 3.109

Review 9.  Aptamer Selection Technology and Recent Advances.

Authors:  Michael Blind; Michael Blank
Journal:  Mol Ther Nucleic Acids       Date:  2016-12-06       Impact factor: 8.886

Review 10.  The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk.

Authors:  Matthew Nayor; Kemar J Brown; Ramachandran S Vasan
Journal:  Circ Res       Date:  2021-01-21       Impact factor: 17.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.